Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
23andMe
MedTech
Wojcicki prevails in 23andMe auction, with final $305M bid
Her $305 million offer topped the previous frontrunner, Regeneron, which bid $256 million to incorporate the DNA tester's assets in its R&D.
Conor Hale
Jun 16, 2025 10:40am
Anne Wojcicki pushes to reopen 23andMe auction
Jun 2, 2025 10:38am
Regeneron’s $256M bid wins 23andMe bankruptcy auction
May 19, 2025 10:37am
Anne Wojcicki steps down to bid on 23andMe’s bankruptcy auction
Mar 24, 2025 10:43am
23andMe shutters cancer drug research, lays off 40% of staff
Nov 11, 2024 9:07pm
23andMine: Anne Wojcicki aims to take genetics company private
Apr 18, 2024 9:16am